MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: New & Novel

The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

Stem cell research & therapy 2017 May 25 [Link] Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A Abstract BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after […]

Comments Off on The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.

Journal of Thoracic Oncology 2017 April [Epub ahead of print] [Link] Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E Abstract INTRODUCTION: BRCA1-associated protein-1, BAP1, is a tumor suppressor involved in multiple cellular processes such as transcriptional regulation, chromatin modification by deubiquitinating histone 2A and DNA repair. BAP1 mutations are […]

Comments Off on A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells

Molecular Cancer 2017 March [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28288645″>Link] He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y Abstract BACKGROUND: Lung cancer and pleural mesothelioma are two of the most deadly forms of cancer. The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding […]

Comments Off on Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells

Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment

Photodiagnosis and photodynamic therapy 2017 February 22 [Epub ahead of print] [Link] Betrouni N, Munck C, Bensoltana W, Baert G, Dewalle-Vignion AS, Scherpereel A, Mordon S Abstract Complete and homogeneous illumination of the target is necessary for the success of a photodynamic therapy (PDT) procedure. In most applications, light dosimetry is done using detectors placed […]

Comments Off on Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment

Anti-CTLA-4 therapy for malignant mesothelioma

Immunotherapy 2017 March [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28231719″>Link] Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L Abstract Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This special report aims […]

Comments Off on Anti-CTLA-4 therapy for malignant mesothelioma

Radiation therapy for malignant pleural mesothelioma

Comments Off on Radiation therapy for malignant pleural mesothelioma

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group

Lung Cancer (Netherlands) 2017 February [Epub 2016 December 15] [Link] Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN Abstract OBJECTIVES: Following failure of a platinum-antifolate combination regimen, there is no standard therapy for advanced malignant pleural mesothelioma (MPM). The […]

Comments Off on A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma

International Journal of Oncology 2017 February 9 [Epub ahead of print] [Link] Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O’Byrne KJ, Cuffe S, Finn SP, Gray SG Abstract Malignant pleural mesothelioma (MPM) is a rare aggressive cancer of the pleura primarily associated with prior exposure to asbestos. The […]

Comments Off on Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma

Chest ultrasonography in health surveillance of asbestos-related lung diseases.

Toxicology and Industrial Health 2017 January [Epub ahead ofprint] [Link] Smargiassi A, Pasciuto G, Pedicelli I, Lo Greco E, Calvello M, Inchingolo R, Schifino G, Capoluongo P, Patriciello P, Manno M, Cirillo A, Corbo GM, Soldati G, Iavicoli I Abstract OBJECTIVES: Exposure to asbestos fibers can lead to different lung diseases, such as pleural thickening […]

Comments Off on Chest ultrasonography in health surveillance of asbestos-related lung diseases.

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Oncotarget 2017 January 18 [Epub ahead of print] [Link] Pei D1, Li Y, Liu X, Yan S, Guo X, Xu X, Guo X Abstract Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. […]

Comments Off on Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis